Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

Cancer

Volumn 80, Issue 10, 1997, Pages 1966-1972

  Bellmunt, Joaquim ^a   Ribas, Antoni ^a   Eres, Natalia ^a   Albanell, Joan ^a   Almanza, Concepción ^a   Bermejo, Begoña ^a   Solé, Luis Alfonso ^a   Baselga, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bladder carcinoma; Carboplatin; Chemotherapy; Cisplatin; M VAC (methotrexate, vinblastine, doxorubicin, and cisplatin)

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INOPERABLE CANCER; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 0030710534     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W     Document Type: Article

References (34)

1. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987;60(Suppl 3):574-85.
2. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12:2264-70.
3. Roth BJ, Bajorin DF. Advanced bladder cancer: the need to identify new agents in the post-MVAC (Methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 1995; 153:894-900.
4. Moore MJ, Tannock I, Ernst S, Huan S, Murray N. Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proceedings of the American Society of Clinical Oncology, May 15, 1996, Philadelphia, PA:250.
5. Yagoda A. Phase II trials in patients with urothelial tumors: Memorial Sloan-Kettering Cancer Center. Cancer Chemother Pharmacol 1993; 11:9-12.
6. Herr HW. Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. J Urol 1980; 123:853-7.
7. Peters PC, O'Neill MR. Cisdiammine-dichlorolatinum as a therapeutic agent in metastatic transitional cell carcinoma. J Urol 1980; 123:375-7.
8. Rossof AM, Talley RW, Stephens RL. Phase II evaluation of cisdichlorodiammineplatinum II in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group study. Cancer Treat Rep 1979;63:1557-64.
9. Loerhrer PJ, Einhorm LH, Elson PJ, Crawford DE, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10:1066-73.
10. Troner M, Birch R, Omura GA, Williams S. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin, and cyclophosphamide in the treatment of bladder cancer: a Southstern Cancer Study Group trial. J Urol 1987;137:660-2.
11. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, et al. Cisplatin, cyclophosphamide, and doxorubicin chemotherapy for unresectable urothelial tumors: the M. D. Anderson experience. J Urol 1989;141:33-7.
12. Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985;3:1463-70.
13. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, et al. Preliminary results of MVAC ( methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133:403-7.
14. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr MN, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64:2448-58.
15. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-5.
16. Mottet-Auselo N, Bons-Rosset F, Costa P, Louis JF, Navratil H. Carboplatin and urothelial tumors. Oncology 1993; 50(Suppl 2):28-36.
17. Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992;70:1974-9.
18. Ruckdeschel JC. The future role of carboplatin. Semin Oncol 1994;21(Suppl 12):114-8.
19. Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D, et al: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Semin Oncol 1994;21(Suppl 6):23-30.
20. Bosl GJ, Bajorin DF. Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparison. Semin Oncol 1994;21(Suppl 12):61-4.
21. Horwich A, Dearnaley DP, Nicholls J, Jay G, Mason M, Harland S, et al. Effectivenes of carboplatin, etoposide and bleomycin in combination chemotherapy in good prognosis metastasic testicular nonseminomatous germ cell tumors. J Clin Oncol 1991;9:62-9.
22. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J Clin Oncol 1993; 11:598-606.
23. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichel J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphmide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 1992; 10:718-26.
24. Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990;8:1556-62.
25. De Andrés L, Brunet J, López-Pousa A, Burgues J, Vega M, Tabernero JM, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995; 13:1493-1500.
26. Eisenberger M, Hornedo J, Silva S, Donehouer R, Spauling M, Van Echo D, et al. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 1986;4:1506-9.
27. Calvert AH, Newel DR, Gumbrell LA, Jackman AL, Sikora E, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
29. Egorin MJ, Jodrell DI. Utility of individualized carboplatin dosing alone and in combination regimens. Semin Oncol 1992;19(Suppl 2):132-8.
30. Chatelut E, Cheverau C, Brunner V, Martinez M, Houin G, Bugat R, et al. A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. Cancer Chemother Pharmacol 1995;35:391-6.
31. Boccardo F, Pace M, Guarneri D, Cannobbio L, Curotto A, Martorana G, et al. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer: a phase II trial. Cancer 1994;73:1932-6.
32. Alexopoulos CG, Vaslamatris M, Papachristoulou A, Papadimitriou V, Dimitriadis A. Combination chemotherapy based on cisplatin or carboplatin in advanced urothelial cancer [abstract]. Ann Oncol 1990; 1(Suppl):77.
33. Van Echo DA, Egorin MJ, Aisner J. The pharmacology of carboplatin. Semin Oncol 1989;16(Suppl 5):1-6.
34. Langer CG, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced nonsmall cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70.